朗姿股份：跨界医美，未能挽救业绩颓势

Core Viewpoint - The medical beauty industry is facing significant challenges, with "difficult operations" becoming a consensus within the sector [1]. Company Performance - Langzi Medical Beauty Group, despite being a listed large chain, is struggling with performance growth. In 2024, the company reported revenue of 5.691 billion yuan, a slight decline from the previous year, and in Q1 2025, revenue further decreased to 1.399 billion yuan, down 7.77% year-on-year. The net profit after deducting non-recurring items was 73.2755 million yuan, a decrease of 6.89% [2]. - The company initially focused on mid-to-high-end women's clothing but faced challenges due to the rise of e-commerce and foreign luxury brands. Despite attempts to diversify into children's clothing, revenue and profit continued to decline [4][5]. - From 2013 to 2015, revenue fell from 1.379 billion yuan to 1.144 billion yuan, and net profit dropped from 204 million yuan to 33 million yuan [5]. Strategic Expansion - Langzi entered the medical beauty market in 2016 through strategic investments and acquisitions, including the purchase of the Korean medical beauty service group DMG and several brands [6][12]. - The company adopted an aggressive acquisition strategy, acquiring multiple medical beauty institutions from 2017 to 2024, aiming to become a leading player in the domestic medical beauty sector [6][8]. Revenue Contribution - By 2024, the medical beauty segment contributed 49% of Langzi's revenue and 45% of its gross profit, surpassing the original women's clothing and children's business contributions [8]. - Despite the successful transition to medical beauty, the expected high growth has not materialized, with the medical beauty segment's revenue growth only at 3.47% year-on-year in 2024 [9]. Profitability Concerns - The gross profit margin for the medical beauty business was 54.42%, lower than the women's clothing (63.45%) and children's business (61.76%) [9]. - The company’s net profit in 2024 was only slightly higher than in 2013, indicating that the transition has not significantly improved profitability [9][10]. Financial Risks - Langzi's goodwill reached 1.781 billion yuan in 2024, accounting for 64% of its net assets, raising concerns about potential impairment risks [13]. - The company faces short-term debt pressures, with 1.323 billion yuan in short-term debt and only 555 million yuan in cash, resulting in a cash-to-short-term-debt ratio of 0.42 [15]. Market Outlook - The medical beauty industry is experiencing intensified competition and slowing growth, compounded by economic challenges and underwhelming consumer recovery [17].